A specific enzyme immunoassay (EIA) for ursodeoxycholic acid 7-N acetylglucosaminides (UDCA-7-NAGs), novel metabolites of ursodeoxycholic acid, has been developed. The EIA was based upon antisera elicited against the glycine conjugated UDCA-7-NAG-bovine serum albumin conjugate and horseradish peroxidase-labeled-UDCA-7-NAG.
Bile acids are synthesized from cholesterol in liver, followed by conjugation with glycine or taurine through the carboxyl group at C-24, and then excreted into bile. In hepatobiliary diseases, the levels in blood and urine of bile acids conjugated further with sulfuric or glucuronic acid, namely the sulfate or glucuronide, respectively, at the 3a-hydroxyl group are significantly elevated. Since the occurrence of the novel conjugate, ursodeoxycholic acid 7-1V acetylglucosaminide (UDCA-7-NAG)'-6, a particular interest has been focused on the physiological significance of this new conjugation. In the previous paper of this series, we have prepared 3-and 7-NAGs of unconjugated, glycine and taurine conjugated bile acid', and developed a detection-oriented derivatization through an inherent primary hydroxyl group of a sugar moiety for the separatory determination of these NAGs by high-performance liquid chromatography (HPLC). 8 Applying the method, 7-NAGs of unconjugated glycine and taurine conjugated ursodeoxycholic acids (UDCAs) have been unambiguously identified in urine of a patient with primary biliary cirrhosis (PBC) after administration of UDCA.6 Other NAGs of common bile acids as well as UDCA 3-NAGs could not be detected. It has been reported that 1V acetylglucosaminyltransferases from human kidney and liver show the substrate specificity only toward 6a-or 7f3-hydroxylated bile acids.2,4 Moreover, it has also been demonstrated that UDCA 7-NAGs are excreted specifically in urine of patient with PBC.
In the preceding papers, the new conjugates have been t To whom correspondence should be addressed .
analyzed by gas chromatography-mass spectrometry) and HPLC.6,s,lo However, a tedious sample treatment procedure is required for the simultaneous determination. A simple and reliable method for the determination of UDCA-7-NAGs is therefore needed for clarifying the novel conjugation related to the diagnosis of PBC.9
The enzyme immunoassay (EIA) has proved to be a method with high sensitivity and specificity for the determination of trace compounds in biological fluids with a simple clean up procedure and will, therefore, be useful for the routine analysis. The present paper deals with the development of EIA for UDCA-7-NAGs and its applicability to human urine specimens.
Experimental Materials Cholic (CA), chenodeoxycholic (CDCA) and ursodeoxycholic (UDCA) acids were purchased from Nacalai Tesque (Tokyo, Japan). Glycine and taurine conjugated bile acids, UDCA 3-and 7-NAGs', and sulfates (S)",'2 were synthesized in these laboratories. Bovine serum albumin (BSA) and horseradish peroxidase (EC 1.1 1.1.7, HRP) (Grade I-C, Reinheitszahl=3.23, 266 units/mg) were supplied by Toyobo (Tokyo, Japan). 3,3',5 ,5 '-Tetramethylbenzidine and complete Freund's adjuvant were purchased from Nacalai Tesque and Iatron Laboratories (Tokyo, Japan), respectively. Goat anti-rabbit Immunoglobulin G (IgG) antiserum and normal rabbit serum were obtained from Daiichi Radioisotope (Tokyo, Japan). All solvents were purified by distillation on a glassware prior to use. Analysis 1H-Nuclear magnetic resonance (NMR) spectra were recorded on a Hitachi R-3000 at 300 MHz with tetramethylsilane as an internal standard. The abbreviations used are s=singlet and d=doublet.
p-Nitrophenyl esters of unconjugated (3) and glycine conjugated ursodeoxycholic acid 7-NA GS (4) A mixture of 7-NAG of UDCA (1, 44 mg) or glycine conjugated UDCA (2, 50 mg) with p-nitrophenol (35 mg for 1, 30 mg for 2) and 1-ethyl(3,3'-dimethylaminopropyl)carbodiimide-HC1(44 mg for 1, 80 mg for 2) in dimethylformamide (3 ml) was stirred at room temperature for 15 -18 h. After evaporation of the solvent, the residue obtained was purified by column chromatography on silica gel (6 g 
Preparation of antisera
A mixture of the activated ester (21 mg of 3, 22 mg of 4) and BSA in pyridine-50 mM phosphate buffer (PB) (pH 8.0) (1:1, v/v) (2 ml) were stirred at 4°C for 2 d. The resulting solution was dialyzed against cold running water at 4° C for 24 h and lyophilized to afford the hapten-BSA conjugate (37 mg of 5, 22 mg of 6) as a fluffy powder. The number of hapten molecules incorporated into a BSA molecule were determined spectrophotometrically (at 309 nm) to be 7 for 5 and 12 for 6 after reaction with concentrated sulfuric acid. 13 The hapten-BSA conjugate obtained (each 1 mg) was dissolved in sterile isotonic saline (0.5 ml) and emulsified with complete Freund's adjuvant (0.5 ml). The emulsion was injected into a domestic female albino rabbit subcutaneously at multiple sites over the back. This procedure was repeated once every fortnight. The antisera prepared from blood by centrifugation at 3000 rpm for 10 min was stored at 4°C.
Preparation of UDCA-7 NAG-HRP conjugate (7) The activated ester 3 (97 jig) in dimethylformamide (0.1 ml) was added to PB (pH 8.5) (0.2 ml) containing HRP (600 µg). The mixture was allowed to stand at 4° C with occasional shaking. The resulting solution ANALYTICAL SCIENCES AUGUST 1996, VOL. 12 was dialyzed against PB (pH 7.3) (3X500 ml), diluted with PB (pH 7.3) to the concentration of 100 µg ml-1 and stored at 4° C. For EIA, this stock solution was diluted with PB (pH 7.3) containing 0.9%(w/v) NaCI and 0.1% (w/v) gelatin.
Procedure for enzyme immunoassay The hapten-enzyme conjugate (40 ng, 100 µl) was mixed with an appropriately diluted urine specimen (0.1 ml) or glycine conjugated UDCA (0 and 0.1-10 ng) in PB (pH 7.3) containing 0.9%(w/v) NaCI and 0.1%(w/ v) gelatin (0.1 ml) and diluted antiserum (0.1 ml), and the mixture was allowed to stand at 4° C for 4 h. To the mixture was added goat anti-rabbit IgG antiserum (0.1 ml) diluted to 1: 30 (v/v) with PB (pH 7.3) containing 0.9%(w/v) NaCI, 0.1%(w/v) gelatin and 0.1% (w/ v) EDTA, and the whole was then allowed to stand at 4° C for 15 h. The resulting mixture was diluted with PB (pH 7.3) (1.5 ml) and centrifuged at 3000 rpm for 10 min. The immune precipitate was collected by aspirating off the supernatant and then washed with PB (pH 7.3) (1.5 ml) by repeating the procedure.
Measurement of enzyme activity
The precipitate was suspended in 0.05 M sodium acetate-citrate buffer (pH 4.2) (1.8 ml) containing 0.42 mM 3,3'5,5'-tetramethylbenzidine and 3%(v/v) dimethylformamide and, following preincubation at 37°C for 3 min, 0.2 ml of 0.01%(v/v) H2O2 was then added. After the mixture was incubated at 37° C for 45 min, 0.05 M H2SO4 (2 ml) was added to terminate the reaction. The absorbances at 450 nm were measured using Hitachi Model 100-20 spectrophotometer.
At the same time, the procedure without addition of the first antibody was carried out to obtain 100% enzymic activity.
Cross-reaction study
The specificity of antisera was assessed by crossreaction studies15 with selected bile acids. The crossreactivity was expressed as the percentage of the amount of glycine conjugated UDCA-7-NAG which reduced the enzyme activity in the precipitate by half to that of the compound listed in Table 1 .
Recovery test
The test sample was prepared by adding amounts of glycine conjugated UDCA-7-NAG urine specimen (0.1 ml) and then subjected analytical procedure described above. Results and Discussion known into a to the
The design of a structure of a hapten molecule is crucial to obtain an antibody with a high affinity toward the small target compound. It is well known that the antibody raised against a hapten molecule usually shows significant cross-reactivity with compounds homologous around the bridge portion used for conjugation with a carrier protein. Therefore, it is necessary to introduce a bridge at the site remote from the inherent structure of the analyte. UDCA-7-NAG possess a characteristic N acetylglucosaminide linkage at 7/3-hydroxyl group on a ring B of a steroid nucleus. Since the total amount of this new conjugate in urine reflects the diagnosis of PBC, discrimination of the conjugated form at C-24 is not always necessary for the purpose of this study. Therefore, the C-24 position was selected as a site suitable for conjugation with a carrier protein (Fig. 1) . Unconjugated and glycine conjugated (G) UDCA-7-NAGs were covalently coupled with BSA to provide UDCA-7-NAG-BSA conjugates by an activated ester method.14 A satisfactory number of hapten moieties (7 for unconjugate and 12 for glycine conjugate) was found in each conjugate. The immunogens thus obtained were administered to rabbits individually with complete Freund's adjuvant subcutaneously, and the appropriate antisera (R-1 from UDCA-7-NAG-BSA and R-2 from glycine conjugated UDCA-7-NAG-BSA) were obtained 8 months after the initial immunization.
In ETA for steroid hormones, the use of a bridge heterologous combination of the enzyme labeled antigen having a shorter bridge structure than that of the immunogen is more favorable to develop a sensitive assay system.15,16 The antiserum used in this study has been prepared by eliciting a rabbit with unconjugated or glycine-conjugated UDCA-7-NAG as a haptenic derivative. Therefore, unconjugated UDCA-7-NAG was covalently coupled to provide UDCA-7-NAG-HRP conjugate by an activated ester method.14 An evaluation of the titer was carried out by incubating various dilutions of antiserum with 40 ng of the UDCA-7-NAG-HRP conjugate. The optimum dilutions of antisera were determined to be 9000 for R-1 and 600 for R-2, respectively. With this dilution of the antiserum, the EIA system provided feasible dose response curves for glycine conjugated UDCA-7-NAG in the range of 0.3 -6 ng/tube (Fig. 2) . The sensitivity obtained with R-2 was superior to that obtained with R-1. This result may be attributed to a difference of binding ability of the enzyme labeled antigen to the antibody. Since the enzyme labeled antigen is prepared by condensation with unconjugated UDCA-7-NAG through the C-24 acidic moiety, it seems that the labeled antigen is more tightly bound with the antibody R-1 than with R-2. Therefore, the enzyme labeled antigen bound to the antibody R-2 is displaced more easily by the analyte, glycine conjugated UDCA-7-NAG, which results in the enhancement of sensitivity.
The specificity of the antisera was characterized by determining the cross-reactivity as the ratio of the amount of glycine conjugated UDCA-7-NAG which reduced the enzyme activity in the bound fraction by half to the amount of related compounds ( Table 1) . As expected, all the antisera exhibited great reactivity with unconjugate and glycine and taurine conjugated UDCA-7-NAG, while no significant competition was observed Table  1 acids Cross-reactivities of antisera with selected bile with 3-sulfates and 3-NAGs of unconjugated, glycine conjugated and taurine conjugated UDCA as well as CA and CDCA. Although the some reactivities were observed with UDCAs and 3-NAGs, the analytical results may not be disturbed, owing to the feeble excreation of UDCAs and the absence of 3-NAGs in urine. No significant differences of the cross reactivities among these antisera were observed. Assessment of the assay reliability was carried out by measuring glycine conjugated UDCA-7-NAG added to bile acid free urine and the recoveries are shown in Table  2 . These data indicate the excellent concordance between expected and measured amounts with acceptable standard deviations. The blank value obtained with charcoal-treated urine was 0.4±0.1 ng/ml. The present method proved to be satisfactory regarding to both precision and accuracy.
The proposed EIA was thus applied to the measurement of urinary conjugated UDCA-7-NAG in urine of patients with PBC during treatment with UDCA (500 mg). All the samples were run as duplicates. The urinary levels of UDCA 7-NAGs observed after correction for blank values ranged from 12 to 18µg/ml, which were similar to those ealier reported values determined by HPLC. 9 The newly developed EIA method will be useful for the clinical and biochemical studies of UDCA related to PBC and other cholestatic diseases. Further studies are being conducted in these laboratories and the details will be reported in the near future.
